Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Chemokine signaling axis between endothelial and myeloid cells regulates development of pulmonary hypertension associated with pulmonary fibrosis and hypoxia.

Oliveira AC, Fu C, Lu Y, Williams MA, Pi L, Brantly ML, Ventetuolo CE, Raizada MK, Mehrad B, Scott EW, Bryant AJ.

Am J Physiol Lung Cell Mol Physiol. 2019 Oct 1;317(4):L434-L444. doi: 10.1152/ajplung.00156.2019. Epub 2019 Jul 31.

PMID:
31364370
2.

Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis.

Gupta N, Lee HS, Young LR, Strange C, Moss J, Singer LG, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Downey GP, Taveira-DaSilva AM, Krischer JP, Setchell K, Trapnell BC, Inoue Y, McCormack FX; NIH Rare Lung Disease Consortium.

Eur Respir J. 2019 Apr 4;53(4). pii: 1802066. doi: 10.1183/13993003.02066-2018. Print 2019 Apr.

PMID:
30846465
3.

Intravenous Alpha-1 Antitrypsin Therapy for Alpha-1 Antitrypsin Deficiency: The Current State of the Evidence.

Brantly ML, Lascano JE, Shahmohammadi A.

Chronic Obstr Pulm Dis. 2018 Nov 28;6(1):100-114. doi: 10.15326/jcopdf.6.1.2017.0185. Review.

4.

Serum Vascular Endothelial Growth Factor D in Cystic Lung Disease.

Ataya A, Riley L, Brantly ML.

JAMA. 2019 Jan 29;321(4):401-402. doi: 10.1001/jama.2018.20926. No abstract available.

PMID:
30605217
5.

A checkpoint on innate myeloid cells in pulmonary arterial hypertension.

Bryant AJ, Fu C, Lu Y, Brantly ML, Mehrad B, Moldawer LL, Brusko TM, Brittain EL, West JD, Austin ED, Hamid R.

Pulm Circ. 2019 Jan-Mar;9(1):2045894018823528. doi: 10.1177/2045894018823528. Epub 2018 Dec 18. No abstract available.

6.

Author Correction: α1-Antitrypsin deficiency.

Greene CM, Marciniak SJ, Teckman J, Ferrarotti I, Brantly ML, Lomas DA, Stoller JK, McElvaney NG.

Nat Rev Dis Primers. 2018 Oct 29;4(1):40. doi: 10.1038/s41572-018-0043-2.

PMID:
30374103
7.

Whole-Genome Sequencing in Severe Chronic Obstructive Pulmonary Disease.

Prokopenko D, Sakornsakolpat P, Fier HL, Qiao D, Parker MM, McDonald MN, Manichaikul A, Rich SS, Barr RG, Williams CJ, Brantly ML, Lange C, Beaty TH, Crapo JD, Silverman EK, Cho MH.

Am J Respir Cell Mol Biol. 2018 Nov;59(5):614-622. doi: 10.1165/rcmb.2018-0088OC.

PMID:
29949718
8.

Bronchoalveolar lavage (BAL) cells in idiopathic pulmonary fibrosis express a complex pro-inflammatory, pro-repair, angiogenic activation pattern, likely associated with macrophage iron accumulation.

Lee J, Arisi I, Puxeddu E, Mramba LK, Amicosante M, Swaisgood CM, Pallante M, Brantly ML, Sköld CM, Saltini C.

PLoS One. 2018 Apr 12;13(4):e0194803. doi: 10.1371/journal.pone.0194803. eCollection 2018. Erratum in: PLoS One. 2018 May 17;13(5):e0197794.

9.

Bioequivalence of a Liquid Formulation of Alpha1-Proteinase Inhibitor Compared with Prolastin®-C (Lyophilized Alpha1-PI) in Alpha1-Antitrypsin Deficiency.

Barker AF, Campos MA, Brantly ML, Stocks JM, Sandhaus RA, Lee D, Steinmann K, Lin J, Sorrells S.

COPD. 2017 Dec;14(6):590-596. doi: 10.1080/15412555.2017.1376044. Epub 2017 Oct 6.

PMID:
28985109
10.

Myeloid-derived Suppressor Cells Are Necessary for Development of Pulmonary Hypertension.

Bryant AJ, Shenoy V, Fu C, Marek G, Lorentsen KJ, Herzog EL, Brantly ML, Avram D, Scott EW.

Am J Respir Cell Mol Biol. 2018 Feb;58(2):170-180. doi: 10.1165/rcmb.2017-0214OC.

11.

Alpha-1 Antitrypsin-Deficient Macrophages Have Increased Matriptase-Mediated Proteolytic Activity.

Krotova K, Marek GW, Wang RL, Aslanidi G, Hoffman BE, Khodayari N, Rouhani FN, Brantly ML.

Am J Respir Cell Mol Biol. 2017 Aug;57(2):238-247. doi: 10.1165/rcmb.2016-0366OC.

12.

α1-Antitrypsin deficiency.

Greene CM, Marciniak SJ, Teckman J, Ferrarotti I, Brantly ML, Lomas DA, Stoller JK, McElvaney NG.

Nat Rev Dis Primers. 2016 Jul 28;2:16051. doi: 10.1038/nrdp.2016.51. Review. Erratum in: Nat Rev Dis Primers. 2018 Oct 29;4(1):40.

PMID:
27465791
13.

Transcription factor Bcl11b sustains iNKT1 and iNKT2 cell programs, restricts iNKT17 cell program, and governs iNKT cell survival.

Uddin MN, Sultana DA, Lorentsen KJ, Cho JJ, Kirst ME, Brantly ML, Califano D, Sant'Angelo DB, Avram D.

Proc Natl Acad Sci U S A. 2016 Jul 5;113(27):7608-13. doi: 10.1073/pnas.1521846113. Epub 2016 Jun 21.

14.

The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult.

Sandhaus RA, Turino G, Brantly ML, Campos M, Cross CE, Goodman K, Hogarth DK, Knight SL, Stocks JM, Stoller JK, Strange C, Teckman J.

Chronic Obstr Pulm Dis. 2016 Jun 6;3(3):668-682. doi: 10.15326/jcopdf.3.3.2015.0182. Review.

15.

In Situ Transplantation of Alginate Bioencapsulated Adipose Tissues Derived Stem Cells (ADSCs) via Hepatic Injection in a Mouse Model.

Chen MJ, Lu Y, Simpson NE, Beveridge MJ, Elshikha AS, Akbar MA, Tsai HY, Hinske S, Qin J, Grunwitz CR, Chen T, Brantly ML, Song S.

PLoS One. 2015 Sep 15;10(9):e0138184. doi: 10.1371/journal.pone.0138184. eCollection 2015.

16.

Practicality of intermittent fasting in humans and its effect on oxidative stress and genes related to aging and metabolism.

Wegman MP, Guo MH, Bennion DM, Shankar MN, Chrzanowski SM, Goldberg LA, Xu J, Williams TA, Lu X, Hsu SI, Anton SD, Leeuwenburgh C, Brantly ML.

Rejuvenation Res. 2015 Apr;18(2):162-72. doi: 10.1089/rej.2014.1624.

17.

Longer telomere length in COPD patients with α1-antitrypsin deficiency independent of lung function.

Saferali A, Lee J, Sin DD, Rouhani FN, Brantly ML, Sandford AJ.

PLoS One. 2014 Apr 24;9(4):e95600. doi: 10.1371/journal.pone.0095600. eCollection 2014.

18.

Genome-wide study of percent emphysema on computed tomography in the general population. The Multi-Ethnic Study of Atherosclerosis Lung/SNP Health Association Resource Study.

Manichaikul A, Hoffman EA, Smolonska J, Gao W, Cho MH, Baumhauer H, Budoff M, Austin JH, Washko GR, Carr JJ, Kaufman JD, Pottinger T, Powell CA, Wijmenga C, Zanen P, Groen HJ, Postma DS, Wanner A, Rouhani FN, Brantly ML, Powell R, Smith BM, Rabinowitz D, Raffel LJ, Hinckley Stukovsky KD, Crapo JD, Beaty TH, Hokanson JE, Silverman EK, Dupuis J, O'Connor GT, Boezen HM, Rich SS, Barr RG.

Am J Respir Crit Care Med. 2014 Feb 15;189(4):408-18. doi: 10.1164/rccm.201306-1061OC.

19.

Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial.

Young L, Lee HS, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Downey GP, Swigris JJ, Taveira-DaSilva AM, Krischer JP, Trapnell BC, McCormack FX; MILES Trial Group.

Lancet Respir Med. 2013 Aug;1(6):445-52.

20.

Safety and pharmacokinetics of 120 mg/kg versus 60 mg/kg weekly intravenous infusions of alpha-1 proteinase inhibitor in alpha-1 antitrypsin deficiency: a multicenter, randomized, double-blind, crossover study (SPARK).

Campos MA, Kueppers F, Stocks JM, Strange C, Chen J, Griffin R, Wang-Smith L, Brantly ML.

COPD. 2013 Dec;10(6):687-95. doi: 10.3109/15412555.2013.800852. Epub 2013 Jul 17.

PMID:
23862647
21.

Cytosolic, autocrine alpha-1 proteinase inhibitor (A1PI) inhibits caspase-1 and blocks IL-1β dependent cytokine release in monocytes.

Wang Y, He Y, Abraham B, Rouhani FN, Brantly ML, Scott DE, Reed JL.

PLoS One. 2012;7(11):e51078. doi: 10.1371/journal.pone.0051078. Epub 2012 Nov 30.

22.

Development, validation and use of ELISA for antibodies to human alpha-1 antitrypsin.

Ye GJ, Oshins RA, Rouhani FN, Brantly ML, Chulay JD.

J Immunol Methods. 2013 Feb 28;388(1-2):18-24. doi: 10.1016/j.jim.2012.11.008. Epub 2012 Nov 27.

PMID:
23195820
23.

Association of cigarette smoking and CRP levels with DNA methylation in α-1 antitrypsin deficiency.

Siedlinski M, Klanderman B, Sandhaus RA, Barker AF, Brantly ML, Eden E, McElvaney NG, Rennard SI, Stocks JM, Stoller JK, Strange C, Turino GM, Campbell EJ, Demeo DL.

Epigenetics. 2012 Jul;7(7):720-8. doi: 10.4161/epi.20319. Epub 2012 Jul 1.

24.

The prevalence of alpha-1 antitrypsin deficiency among patients found to have airflow obstruction.

Rahaghi FF, Sandhaus RA, Brantly ML, Rouhani F, Campos MA, Strange C, Hogarth DK, Eden E, Stocks JM, Krowka MJ, Stoller JK.

COPD. 2012 Aug;9(4):352-8. doi: 10.3109/15412555.2012.669433. Epub 2012 Apr 16. Erratum in: COPD. 2013 Aug;10(4):555. Brantly, Mark L [added]; Rouhani, Farshid [added]; Campos, Michael A [added].

PMID:
22506682
25.

Association of IREB2 and CHRNA3 polymorphisms with airflow obstruction in severe alpha-1 antitrypsin deficiency.

Kim WJ, Wood AM, Barker AF, Brantly ML, Campbell EJ, Eden E, McElvaney G, Rennard SI, Sandhaus RA, Stocks JM, Stoller JK, Strange C, Turino G, Silverman EK, Stockley RA, Demeo DL.

Respir Res. 2012 Feb 22;13:16. doi: 10.1186/1465-9921-13-16.

26.

Efficacy and safety of sirolimus in lymphangioleiomyomatosis.

McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Young LR, Kinder BW, Downey GP, Sullivan EJ, Colby TV, McKay RT, Cohen MM, Korbee L, Taveira-DaSilva AM, Lee HS, Krischer JP, Trapnell BC; National Institutes of Health Rare Lung Diseases Consortium; MILES Trial Group.

N Engl J Med. 2011 Apr 28;364(17):1595-606. doi: 10.1056/NEJMoa1100391. Epub 2011 Mar 16.

27.

Alpha-1 antitrypsin protein and gene therapies decrease autoimmunity and delay arthritis development in mouse model.

Grimstein C, Choi YK, Wasserfall CH, Satoh M, Atkinson MA, Brantly ML, Campbell-Thompson M, Song S.

J Transl Med. 2011 Feb 24;9:21. doi: 10.1186/1479-5876-9-21.

28.

Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study.

Stocks JM, Brantly ML, Wang-Smith L, Campos MA, Chapman KR, Kueppers F, Sandhaus RA, Strange C, Turino G.

BMC Clin Pharmacol. 2010 Sep 30;10:13. doi: 10.1186/1472-6904-10-13.

29.

Alpha₁-antitrypsin deficiency-related alleles Z and S and the risk of Wegener's granulomatosis.

Mahr AD, Edberg JC, Stone JH, Hoffman GS, St Clair EW, Specks U, Dellaripa PF, Seo P, Spiera RF, Rouhani FN, Brantly ML, Merkel PA.

Arthritis Rheum. 2010 Dec;62(12):3760-7. doi: 10.1002/art.27742.

30.

Augmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies.

Tonelli AR, Brantly ML.

Ther Adv Respir Dis. 2010 Oct;4(5):289-312. doi: 10.1177/1753465810373911. Epub 2010 Jul 22. Review.

PMID:
20650978
31.

Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank.

Tonelli AR, Rouhani F, Li N, Schreck P, Brantly ML.

Int J Chron Obstruct Pulmon Dis. 2009;4:443-52. Epub 2009 Dec 29.

32.

Quantitative airway assessment on computed tomography in patients with alpha1-antitrypsin deficiency.

Yamashiro T, Matsuoka S, Estépar RS, Diaz A, Newell JD, Sandhaus RA, Mergo PJ, Brantly ML, Murayama S, Reilly JJ, Hatabu H, Silverman EK, Washko GR.

COPD. 2009 Dec;6(6):468-77. doi: 10.3109/15412550903341521.

33.

Alveolar macrophage dysregulation in Hermansky-Pudlak syndrome type 1.

Rouhani FN, Brantly ML, Markello TC, Helip-Wooley A, O'Brien K, Hess R, Huizing M, Gahl WA, Gochuico BR.

Am J Respir Crit Care Med. 2009 Dec 1;180(11):1114-21. doi: 10.1164/rccm.200901-0023OC. Epub 2009 Sep 3.

34.

Development of predictive models for airflow obstruction in alpha-1-antitrypsin deficiency.

Castaldi PJ, DeMeo DL, Kent DM, Campbell EJ, Barker AF, Brantly ML, Eden E, McElvaney NG, Rennard SI, Stocks JM, Stoller JK, Strange C, Turino G, Sandhaus RA, Griffith JL, Silverman EK.

Am J Epidemiol. 2009 Oct 15;170(8):1005-13. doi: 10.1093/aje/kwp216. Epub 2009 Sep 2.

35.

Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy.

Brantly ML, Chulay JD, Wang L, Mueller C, Humphries M, Spencer LT, Rouhani F, Conlon TJ, Calcedo R, Betts MR, Spencer C, Byrne BJ, Wilson JM, Flotte TR.

Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16363-8. doi: 10.1073/pnas.0904514106. Epub 2009 Aug 12. Erratum in: Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17606.

36.

Heritability of lung function in severe alpha-1 antitrypsin deficiency.

DeMeo DL, Campbell EJ, Brantly ML, Barker AF, Eden E, McElvaney NG, Rennard SI, Stocks JM, Stoller JK, Strange C, Turino G, Sandhaus RA, Silverman EK.

Hum Hered. 2009;67(1):38-45. doi: 10.1159/000164397. Epub 2008 Oct 17.

37.

Alpha-1-antitrypsin aerosolised augmentation abrogates neutrophil elastase-induced expression of cathepsin B and matrix metalloprotease 2 in vivo and in vitro.

Geraghty P, Rogan MP, Greene CM, Brantly ML, O'Neill SJ, Taggart CC, McElvaney NG.

Thorax. 2008 Jul;63(7):621-6. doi: 10.1136/thx.2007.088559. Epub 2008 Feb 4.

PMID:
18250185
38.

Prevalence of alpha-1 antitrypsin deficiency in poorly controlled asthma--results from the ALA-ACRC low-dose theophylline trial.

Eden E, Holbrook JT, Brantly ML, Turino GM, Wise RA.

J Asthma. 2007 Oct;44(8):605-8.

PMID:
17943569
39.

IL10 polymorphisms are associated with airflow obstruction in severe alpha1-antitrypsin deficiency.

Demeo DL, Campbell EJ, Barker AF, Brantly ML, Eden E, McElvaney NG, Rennard SI, Sandhaus RA, Stocks JM, Stoller JK, Strange C, Turino G, Silverman EK.

Am J Respir Cell Mol Biol. 2008 Jan;38(1):114-20. Epub 2007 Aug 9.

40.

Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency.

Demeo DL, Sandhaus RA, Barker AF, Brantly ML, Eden E, McElvaney NG, Rennard S, Burchard E, Stocks JM, Stoller JK, Strange C, Turino GM, Campbell EJ, Silverman EK.

Thorax. 2007 Sep;62(9):806-13. Epub 2007 Mar 27.

41.

Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults.

Brantly ML, Spencer LT, Humphries M, Conlon TJ, Spencer CT, Poirier A, Garlington W, Baker D, Song S, Berns KI, Muzyczka N, Snyder RO, Byrne BJ, Flotte TR.

Hum Gene Ther. 2006 Dec;17(12):1177-86.

PMID:
17115945
42.

Does the heterozygous state of alpha-1 antitrypsin deficiency have a role in chronic liver diseases? Interim results of a large case-control study.

Regev A, Guaqueta C, Molina EG, Conrad A, Mishra V, Brantly ML, Torres M, De Medina M, Tzakis AG, Schiff ER.

J Pediatr Gastroenterol Nutr. 2006 Jul;43 Suppl 1:S30-5.

PMID:
16819398
43.

Genetic testing of minors for alpha1-antitrypsin deficiency.

Strange C, Moseley MA, Jones Y, Schwarz L, Xie L, Brantly ML.

Arch Pediatr Adolesc Med. 2006 May;160(5):531-4.

PMID:
16651497
44.

Short-term atorvastatin treatment enhances specific antibody production following tetanus toxoid vaccination in healthy volunteers.

Lee PY, Scumpia PO, Byars JA, Kelly KM, Zhuang H, Shuster JS, Theriaque DW, Segal MS, Reeves WH, Brantly ML.

Vaccine. 2006 May 8;24(19):4035-40. Epub 2006 Jan 9.

PMID:
16464519
46.

Antibody response to aerosolized transgenic human alpha1-antitrypsin.

Spencer LT, Humphries JE, Brantly ML; Transgenic Human Alpha 1-Antitrypsin Study Group.

N Engl J Med. 2005 May 12;352(19):2030-1. No abstract available.

PMID:
15888711
47.

[American Thoracic Society/European Respiratory Society Statement: Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency].

Stoller JK, Snider GL, Brantly ML, Fallat RJ, Stockley RA, Turino GM, Konietzko N, Dirksen A, Eden E, Fallat RJ, Luisetti M, Stolk J, Strange C; American Thoracic Society; European Respiratory Society.

Pneumologie. 2005 Jan;59(1):36-68. German. No abstract available.

PMID:
15685488
48.

Genetic testing for alpha1-antitrypsin deficiency.

Strange C, Dickson R, Carter C, Carpenter MJ, Holladay B, Lundquist R, Brantly ML.

Genet Med. 2004 Jul-Aug;6(4):204-10.

PMID:
15266208
49.

Z alpha1-antitrypsin polymerizes in the lung and acts as a neutrophil chemoattractant.

Mulgrew AT, Taggart CC, Lawless MW, Greene CM, Brantly ML, O'Neill SJ, McElvaney NG.

Chest. 2004 May;125(5):1952-7.

PMID:
15136414
50.

Differential metabolic effects of saturated versus polyunsaturated fats in ketogenic diets.

Fuehrlein BS, Rutenberg MS, Silver JN, Warren MW, Theriaque DW, Duncan GE, Stacpoole PW, Brantly ML.

J Clin Endocrinol Metab. 2004 Apr;89(4):1641-5.

PMID:
15070924

Supplemental Content

Loading ...
Support Center